50 results about "Brain cancer" patented technology

A three-dimensional scaffold for use in engineered tissue includes a repeated 3D geometry; and at least one of a hydrogel, a biocompatible polymer, and a bioprintable polymer. The repeated 3D geometry may include an open geometry including a plurality of interconnected nodes configured to be seeded with living cells. The scaffold may be formed via bioprinting. The three-dimensional scaffold may also be used for (1) 3D tissue modelling (for liver, kidney, gut, pancreas, heart, lung, spleen, etc.), (2) disease modeling of different tumor types such as breast, colorectal, lung, liver, brain, ovarian and others, (3) drug testing / therapeutic screening of small molecule drugs, peptides, proteins, antibodies, ADCs, gene therapies, RNA-based therapeutics, cell therapies, and tissue therapies, and (4) therapeutic / drug delivery (i.e., via delivery device that can be used to control drug release based on different patterns).

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with CNS disorders. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating cognitive impairment associated with CNS disorders in a subject in need or at risk thereof, including age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI, Age-Associated Memory Impairment, Age Related Cognitive Decline, dementia, Alzheimer's Disease (AD), prodromal AD, PTSD, schizophrenia, bipolar disorder, ALS, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer. Also disclosed herein is a method of treating brain cancer in a subject in need thereof, comprising administering a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the compound, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is brain-penetrating.

Described herein are particle-driven radiogenomics systems and methods that can be used to identify imaging features for prediction of intratumoral and interstitial nanoparticle distributions in cancers (e.g., in low grade and / or high-grade brain cancers (e.g., gliomas, e.g., primary gliomas)). In certain embodiments, the systems and methods described herein extract and combine quantitative multi-dimensional data generated from structural, functional, and / or metabolic imaging. In certain embodiments, the combined multidimensional data is linked to intratumoral and interstitial nanoparticle distributions. For example, this linked data can be used to determine quantitative functional-metabolic multimodality particle-based imaging features and to predict treatment efficacy. These techniques provide an improved quantitative ability to measure treatment response and determine tumor progressions compared to traditional size-based imaging methods.

The present invention relates to methods, compositions, and combinations for inhibiting the NLRP3 inflammasome and / or LON protease as well as methods, compositions, and combinations for treating cancer, particularly blood cancer or brain cancer. In certain aspects, the compositions and combinations include a synthetic triterpenoid, such as 1-[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4(-pyridin-2-yl)-1H-imidazole (“CDDO-2P-Im”) and 1-[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4(-pyridin-3-yl)-1H-imidazole (“CDDO-3P-Im”).

The present disclosure relates to an oral dosage form, such as a capsule, comprising (a) mirdametinib having a d90 no more than 250 microns, a d50 no more than 50 microns, or both, and (b) one or more pharmaceutically acceptable excipients. These dosage forms are useful in the treatment of tumors and cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), high grade glioma (HGG), low grade ovarian cancer, Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain. The disclosure also related to improved dosage regimens for mirdametinib treatments.

Provided herein are nanoparticles comprising a triblock copolymer and a targeting moiety for targeted delivery of one or more therapeutic agents, and formulations thereof. Also provided herein are layered drug delivery vehicles. Further provided herein are methods, or uses thereof, for treating cancers, preferably pancreatic and brain cancers, by administration of the nanoparticles disclosed herein.

The present invention relates to the identification and use of tumor epitopes from subjects with brain cancer, and particularly to epitopes from brevican, neurocan, versican, and aggrecan and their use in formulating cancer vaccines for treatment of tumor patients. In some preferred embodiments the methods provide a means of identifying T cell epitopes in proteins upregulated in brain tumors and the selection of those peptides which can stimulate T cell responses in individual subjects with a particular combination of HLA alleles. It further identifies the T cell exposed motifs comprised in T cell epitopes and enables the design of peptides with alternative amino acids in positions other than the T cell exposed motifs. In preferred embodiments, the MHC I and MHC II alleles of the affected subject are determined, and peptides are selected which bind to their MHC molecules with a desired affinity to elicit stimulation.

The disclosure provides a liposome nanoparticle, a pharmaceutical composition comprising liposome nanoparticles, and a method of treating brain cancer. In some aspects, the liposome nanoparticle comprising a folate bearing lipid and nucleic acid molecules (e.g., siRNA or shRNA) that reduce the expression of H2.0 Like Homeobox (HLX). The liposome nanoparticle optionally comprises a diameter of about 50 nm to about 400 nm. In some aspects, the pharmaceutical composition comprises the liposome nanoparticles and a pharmaceutically acceptable carrier, diluent, or excipient. In some aspects, the method of treating brain cancer comprises administering to a subject in need thereof the liposome nanoparticle.

The present invention relates to a therapeutic composition from natural substances that targets cancer cells, specifically brain cancer cells, and to a method for preparing same, wherein the composition comprises: 1) a therapeutic agent extracted from black seed, in the form of thymoquinone and 2) between 238,671 and 1,500,000,000 platelets, wherein components (a) and (b) are dissolved in 1 mL blood plasma proteins.

To provide a method for treating a disease.SOLUTION: Tricyclic PARP1 inhibitors and pharmaceutical compositions comprising the inhibitors are described herein. The subject compounds and compositions are useful for the treatment of cancer. Also disclosed herein is a method for treating a subject in need of treatment of brain cancer, the method comprising administering a compound disclosed herein or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the compound or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof is brain penetrant.SELECTED DRAWING: None

A substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c]quinolin-2-one derivative (represented by the formula (I)) free base's crystal form and salt's crystal form, a preparation method and application are provided; specifically, the free base crystal form and fumarate salt crystal form of the 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c]quinolin-2-one derivative represented by formula (I). The free base crystal form and salt crystal form provided by the present invention have good stability, which can be used in the treatment of cancers, cancers with CNS metastasis, meningeal metastasis, primary brain cancer or glioma, etc., especially combination with DNA double strand break inducing agents, and have good bioavailability and half-life, which are of great significance for further research on the efficacy of such solid drugs.

The presently disclosed subject matter provides compositions, methods, and kits for transfecting adipose-derived mesenchymal stem cells (AMSCs) in freshly extracted adipose tissue using nanoparticles comprising biodegradable polymers self-assembled with nucleic acid molecules. The presently disclosed subject matter also provides methods for treating a neurological disease in a patient in need thereof, the method comprising administering the AMSCs transfected with the nucleic acid molecules to the patient, wherein the nucleic acid molecules encode one or more bioactive molecules functional in the treatment of a neurological disease, particularly wherein the neurological disease is a brain tumor.

Described is a low voltage, pulsed electrical stimulation device for controlling expression of growth differentiation factor 10 (“GDF10”), a useful protein, by tissues. Also described are methods of enhancing expression of GDF10 in cells, particularly a method of stimulating the expression and / or release of GDF10 in a cell having a gene encoding GDF10, wherein the method includes applying a bioelectric signal produces, as measured at the level of the target cells or tissues being stimulated 2 mA to 4 mA direct current positive to the cell (e.g., directly, indirectly, or wirelessly). Applications in the treatment of cerebral strokes, brain injuries, paralysis, brain cancer, Alzheimer's disease, dementia, anxiety, Parkinson's disease, and / or essential tremors are also disclosed.

The present invention relates to use of a novel compound capable of functioning as a molecular adhesive for preventing or treating brain cancer.

The invention relates to a compound of formula (I), wherein, for example, - Z is representing a group (II), wherein R5 is representing NR6R7 group and wherein R6 and R7 represent independently a hydrogen - R4 is representing a O-aryl ring, - X is representing a NR2R3 group, wherein R2 and R3 are independently hydrogen and a (C1- C10)alkyl group, - R1 is representing a group (III), for its use in the prevention or the treatment of one of the following brain cancers chosen among: glioblastoma, astrocytoma, oligodendroglioma, medulloblastoma, ependymoma, meningioma, pineoblastoma, or in the prevention or the treatment of epilepsies or infantile epilepsies.

The present invention relates to methods, compositions, and combinations for inhibiting the NLRP3 inflammasome and / or LON protease as well as methods, compositions, and combinations for treating cancer, particularly blood cancer or brain cancer. In certain aspects, the compositions and combinations include a synthetic triterpenoid, such as 1-[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4(-pyridin-2-yl)-1H-imidazole (“CDDO-2P-Im”) and 1-[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4(-pyridin-3-yl)-1H-imidazole (“CDDO-3P-Im”).

The present application describes various implementations of devices, systems, and methods for electrical treatment of cancer in the brain. The systems can include an implanted component with a hub and two flexible electrodes, wirelessly connectable to an external retriever for transmission of power and data. The systems may provide stimulation to and / or recording from the target brain tissue. Systems and methods for implantation of one or more components are also described. Such systems can include a center stylet, a hollow insertion needle, and an outer tube for releasably retaining the implanted electrode and hub during an insertion procedure.

The novel compounds, compositions, and methods disclosed herein are effective for treating subjects suspected of having or developing a condition, such as cancer (i.e., brain cancer or cancer that has metastasized to the brain). A method for treating cancer can include administering to a subject a pharmaceutical composition comprising at least one of the novel compounds disclosed herein, and optionally one or more additional anti-cancer therapies. The compounds, compositions, and methods can further be used for drug screening and other detection and isolation methods.

Methods for inhibiting, reducing, or stopping the growth of central nervous system cancers, such as brain tumors, or cancers influenced by the nervous system are described herein. The methods also include, in some instances, reducing or maintaining the size or volume of such cancers. Such methods are useful for treating and combatting aggressive brain cancers.

Nanoparticles comprising miR-211 and their use for treating brain cancers, such as medulloblastomas, including pediatric medulloblastomas, are disclosed.

The present disclosure relates to a method of preventing or treating brain cancers or brain metastases with mesoporous silica nanoparticles (MSNs) loaded with taxane-based chemotherapeutic drugs, in particular paclitaxel (PTX), cabazitaxel (CTX) or docetaxel (DTX), and the MSNs loaded with PTX, CTX or DTX.

Provided herein are methods of treating brain cancer in a subject, comprising evaluating one or more biological samples from a subject who has brain cancer for the presence of a miRNAs and administering interleukin-12 (IL-12); an immunogenic composition of human telomerase reverse transcriptase (hTERT), Wilms Tumor-1 (WT-1), and prostate specific membrane antigen (PSMA); and an anti-programmed cell death receptor 1 (PD-1) antibody to said subject if the subject has an increased expression level of the mIR-331-3p miRNA or isomiRs thereof and the miR-1537-3p miRNA or isomiRs thereof relative to a control population of subjects. Also provided herein are methods of treating brain cancer in a subject, comprising measuring an expression level of at least one mRNA biomarker selected from SYNGR3, OTX1, GABBR2, LHX1, CADM3, MLLT11, MNX1, GRB14, SLC34A2, PHYHIP, WNT10B, SLC17A6, CRLF1, HOXD13, TGFβR3, UBA7, SFRP4, or any combination thereof, in a tumor sample from a subject and administering IL-12; an immunogenic composition hTERT, WT-1, and PSMA; and an anti-PD-1 antibody to said subject if the expression level of SYNGR3, OTX1, GABBR2, LHX1, CADM3, MLLT11, MNX1, GRB14, SLC34A2, PHYHIP, WNT10B, SLC17A6, CRLF1 and HOXD13 is decreased or if the expression level of TGFβR3, UBA7, SFRP4 is increased.

Described herein are crystalline forms of (R)-N-(1-(4-aminobenzyl)-1H-pyrazol-4 -yl)-9-methyl-6-oxo-6,7,8,9-tetrahydropyrido [3′,2′: 4,5]-pyrrolo [1,2-a]pyrazine-2-carboxamide hydrochloride and solvates thereof; pharmaceutical compositions and use thereof in treating cancer such as breast cancer, prostate cancer, lung cancer, brain cancer, skin cancer, bone cancer, ovarian cancer, multiple myeloma and leukemia. Compound (I).

The novel compounds, compositions, and methods disclosed herein are effective for treating subjects suffering from or suspected of suffering from a health condition (e.g., cancer (i.e., brain cancer or cancer metastatic to the brain). Methods of treating cancer may comprise administering to a subject a pharmaceutical composition comprising at least one novel compound disclosed herein, and optionally more than one other anti-cancer therapy. These compounds, compositions, and methods may also be used in drug screening, as well as other detection and isolation methods.

Peptides of D-amino acids and their use in therapy, for example treating or preventing brain cancer, as well as pharmaceutical compositions comprising the peptides, the peptides being effective modulators of matrix metalloproteinases (MMPs).

The present invention relates to a method for preparing a melatonin-producing miniature pig cell line, and a use thereof. It has been confirmed that a miniature pig-derived pineal gland cell line of the present invention may be used as a pineal gland cell line by having a single-characteristic cell line isolated. In addition, it has been confirmed that, in the isolated pineal gland cell line, the pineal gland markers and melatonin synthesis proteins AANAT, ASMT, SAG, ADRB1, and SLC15A1 are expressed, and it has been confirmed that serotonin and melatonin secreted by pinealocytes are extracellularly secreted. In addition, it has been confirmed that the pineal gland cell line expresses pineal gland markers and proteins. In addition, it has been confirmed that, in a cell line in which the pineal gland cell line has MTNR1A marked with red fluorescence, fluorescence expression increases in a melatonin-dependent manner, and the fluorescence expression and MTNR1A are reduced due to a melatonin antagonist, and thus it has been confirmed that the present invention may be used for brain disease or brain cancer screening by using same.

The present disclosure relates to fluorinated phenylamino compounds, their pharmaceutical compositions, and methods for treating one or more tumors or cancers selected from the group consisting of plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), cutaneous neurofibromas (cNF), pancreatic ductal adenocarcinoma (PDAC), high grade glioma (HGG), low grade ovarian cancer, tuberous sclerosis (TSC), Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain, comprising administering to a patient in need thereof, those pharmaceutical compositions.

Described herein is 6-(6-(((1R,2R,3S,5S)-2-fluoro-9-azabicyclo[3.3.1]nonan-3-yl)(methyl)amino)pyridazin-3-yl)-2-methylbenzo[d]oxolan-5-ol (Structure B), a small molecule splicing modulator (SMSM) of mRNA encoded by a gene, such as a pre-mRNA, for use in the treatment of neurological and neurodegenerative diseases, such as Huntington's disease and brain cancer.

There exist in NATURE a number of microscopic organisms that exhibit survival traits under extreme conditions. Several exhibit survival traits under extensive radiation fields. One such organism is Deinococcus Radiodurans. (refer to Refs 1 a and 1 b of PRIOR ART) We believe that this survival trait is genetically based. We claim that this genetic trait can be utilized for enhancement of radiation susceptibility and resistance and can be encapsulated in a pharmaceutical. This is partially confirmed in Ref 1c for a human cell system (refer to the PRIOR ART section), and justifies our Patent. We claim as our invention a pharmaceutical selectively utilizing the Deinococcus Radiodurans genes, and DNA / RNA genetic as well as chemical repair system, for the application to radiation treatment of human Glioblastoma Brain Cancer. We claim that we can utilize this pharmaceutical for the targeted enhancement of radiation susceptibility and resistance in the cancerous and healthy tissues, using energetic Protons or Carbon lons and the associated Bragg Peak selected energy deposition for these regions. We claim that this pharmaceutical can also be utilized with other focused radiation modalities such as X-Rays or electron beams, but not as effectively. We specifically select the DR1709 Deinococcus Radiodurans gene for this application and the DrRRA(DR2418) Deinococcus Radiodurans gene for this application. We do not exclude other Deinococcus Radiodurans genes, and DNA / RNA genetic as well as chemical repair systems not known at this time to this inventor currently or in the future. We do not exclude genes of other micro-organisms that survive under extreme conditions. However, only the application of radiation resistant micro-organism genetic material to create a pharmaceutical for the control of radiation resistance and susceptibility is being patented with a specific organism and gene set as the basis of this Patent (i.e., Deinococcus Radiodurans) and the application to the radiation treatment of human Glioblastoma Brain Cancer.